JP2018506277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506277A5 JP2018506277A5 JP2017539650A JP2017539650A JP2018506277A5 JP 2018506277 A5 JP2018506277 A5 JP 2018506277A5 JP 2017539650 A JP2017539650 A JP 2017539650A JP 2017539650 A JP2017539650 A JP 2017539650A JP 2018506277 A5 JP2018506277 A5 JP 2018506277A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- der
- seq
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108010071690 Prealbumin Proteins 0.000 claims 8
- 102000009190 Transthyretin Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109002P | 2015-01-28 | 2015-01-28 | |
| US62/109,002 | 2015-01-28 | ||
| US201562266556P | 2015-12-11 | 2015-12-11 | |
| US62/266,556 | 2015-12-11 | ||
| PCT/IB2016/050415 WO2016120810A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133642A Division JP7028923B2 (ja) | 2015-01-28 | 2020-08-06 | 抗トランスサイレチン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506277A JP2018506277A (ja) | 2018-03-08 |
| JP2018506277A5 true JP2018506277A5 (enExample) | 2019-03-07 |
| JP6748086B2 JP6748086B2 (ja) | 2020-09-02 |
Family
ID=55299694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539650A Active JP6748086B2 (ja) | 2015-01-28 | 2016-01-28 | 抗トランスサイレチン抗体 |
| JP2020133642A Active JP7028923B2 (ja) | 2015-01-28 | 2020-08-06 | 抗トランスサイレチン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020133642A Active JP7028923B2 (ja) | 2015-01-28 | 2020-08-06 | 抗トランスサイレチン抗体 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20160251418A1 (enExample) |
| EP (2) | EP3250592B1 (enExample) |
| JP (2) | JP6748086B2 (enExample) |
| KR (2) | KR102598180B1 (enExample) |
| CN (1) | CN107406499B (enExample) |
| AU (1) | AU2016210888C1 (enExample) |
| CA (1) | CA2974912A1 (enExample) |
| CL (2) | CL2017001924A1 (enExample) |
| CO (1) | CO2017008476A2 (enExample) |
| CU (1) | CU24480B1 (enExample) |
| DK (1) | DK3250592T3 (enExample) |
| EA (1) | EA036080B1 (enExample) |
| ES (1) | ES2934656T3 (enExample) |
| FI (1) | FI3250592T3 (enExample) |
| HR (1) | HRP20221538T1 (enExample) |
| HU (1) | HUE060878T2 (enExample) |
| IL (1) | IL253633B (enExample) |
| LT (1) | LT3250592T (enExample) |
| MX (1) | MX394170B (enExample) |
| PE (1) | PE20180217A1 (enExample) |
| PH (1) | PH12017501318B1 (enExample) |
| PL (1) | PL3250592T3 (enExample) |
| PT (1) | PT3250592T (enExample) |
| RS (1) | RS63906B1 (enExample) |
| SA (1) | SA517382002B1 (enExample) |
| SG (2) | SG10202101763VA (enExample) |
| SI (1) | SI3250592T1 (enExample) |
| TW (2) | TWI786505B (enExample) |
| UA (1) | UA122142C2 (enExample) |
| WO (1) | WO2016120810A1 (enExample) |
| ZA (1) | ZA201705663B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7076711B2 (ja) * | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| PE20210042A1 (es) | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
| CN111315213B (zh) | 2017-10-06 | 2023-09-12 | 普罗塞纳生物科学有限公司 | 抗甲状腺素运载蛋白抗体 |
| EA202091130A1 (ru) * | 2017-11-29 | 2020-08-28 | Протена Биосайенсис Лимитед | Лиофилизованный препарат моноклонального антитела к транстиретину |
| EP3876713B1 (en) | 2018-11-09 | 2024-10-02 | Neurimmune AG | Patient-derived amyloid xenograft rodent model |
| EP4121766A1 (en) | 2020-03-18 | 2023-01-25 | AL-S Pharma AG | Misfolded sod1 assay |
| CA3172824A1 (en) | 2020-05-12 | 2021-11-18 | Neurimmune Ag | Combination therapy for ttr amyloidosis |
| US20230340089A1 (en) * | 2020-05-14 | 2023-10-26 | City Of Hope | Smc1a antibodies and uses thereof |
| JP2023548005A (ja) * | 2020-10-28 | 2023-11-15 | ノヴォ ノルディスク アー／エス | 抗トランスサイレチン抗体およびその使用方法 |
| CN113845593B (zh) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | 抗α-SMA蛋白单克隆抗体、细胞系及其应用 |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| US20240228637A9 (en) * | 2022-10-19 | 2024-07-11 | Ibio, Inc. | Chemokine receptor 8 (ccr8) antibodies |
| WO2024105062A1 (en) | 2022-11-15 | 2024-05-23 | Neurimmune Ag | Methods for treating or preventing transthyretin-mediated amyloidosis |
| CN121263449A (zh) | 2023-03-21 | 2026-01-02 | 拜格拉夫55公司 | Cd19/cd38多特异性抗体 |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| TW202528347A (zh) | 2023-11-15 | 2025-07-16 | 瑞士商紐立慕公司 | 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法 |
| WO2025125544A1 (en) | 2023-12-15 | 2025-06-19 | Novo Nordisk A/S | Stable liquid formulations |
| WO2025238147A1 (en) | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| JP2002536750A (ja) | 1999-02-05 | 2002-10-29 | サムスン エレクトロニクス カンパニー リミテッド | 映像テキスチャー抽出方法及びその装置 |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| DE60220719T2 (de) | 2001-12-28 | 2008-03-06 | Amgen Fremont Inc. | Antikörper gegen das muc18-antigen |
| BR0316525A (pt) | 2002-11-29 | 2005-10-04 | Boehringer Ingelheim Pharma | Genes de fosfotransferase de neomicina e processos para seleção de células recombinantes de alta produtividade |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2006051065A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| WO2007124345A2 (en) | 2006-04-21 | 2007-11-01 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| PT2126093E (pt) | 2007-03-02 | 2012-12-03 | Boehringer Ingelheim Pharma | Melhoramento da produção de proteínas |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| FI20115165A0 (fi) * | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| EP2953970A4 (en) * | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | TRANSTYRETIN ANTIBODIES AND USES THEREOF |
| US20160168235A1 (en) * | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| PE20210042A1 (es) | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
-
2016
- 2016-01-27 TW TW110100085A patent/TWI786505B/zh active
- 2016-01-27 TW TW105102535A patent/TWI718122B/zh active
- 2016-01-28 CN CN201680010882.7A patent/CN107406499B/zh active Active
- 2016-01-28 EP EP16702812.5A patent/EP3250592B1/en active Active
- 2016-01-28 PL PL16702812.5T patent/PL3250592T3/pl unknown
- 2016-01-28 DK DK16702812.5T patent/DK3250592T3/da active
- 2016-01-28 CA CA2974912A patent/CA2974912A1/en active Pending
- 2016-01-28 SG SG10202101763VA patent/SG10202101763VA/en unknown
- 2016-01-28 LT LTEPPCT/IB2016/050415T patent/LT3250592T/lt unknown
- 2016-01-28 JP JP2017539650A patent/JP6748086B2/ja active Active
- 2016-01-28 PT PT167028125T patent/PT3250592T/pt unknown
- 2016-01-28 KR KR1020177023749A patent/KR102598180B1/ko active Active
- 2016-01-28 SG SG11201706124VA patent/SG11201706124VA/en unknown
- 2016-01-28 KR KR1020237037602A patent/KR102677203B1/ko active Active
- 2016-01-28 HR HRP20221538TT patent/HRP20221538T1/hr unknown
- 2016-01-28 MX MX2017009806A patent/MX394170B/es unknown
- 2016-01-28 US US15/009,662 patent/US20160251418A1/en not_active Abandoned
- 2016-01-28 SI SI201631652T patent/SI3250592T1/sl unknown
- 2016-01-28 AU AU2016210888A patent/AU2016210888C1/en active Active
- 2016-01-28 UA UAA201708667A patent/UA122142C2/uk unknown
- 2016-01-28 PE PE2017001287A patent/PE20180217A1/es unknown
- 2016-01-28 ES ES16702812T patent/ES2934656T3/es active Active
- 2016-01-28 WO PCT/IB2016/050415 patent/WO2016120810A1/en not_active Ceased
- 2016-01-28 EP EP22195219.5A patent/EP4134379A1/en active Pending
- 2016-01-28 CU CU2017000097A patent/CU24480B1/es unknown
- 2016-01-28 FI FIEP16702812.5T patent/FI3250592T3/fi active
- 2016-01-28 HU HUE16702812A patent/HUE060878T2/hu unknown
- 2016-01-28 RS RS20221170A patent/RS63906B1/sr unknown
- 2016-01-28 EA EA201791712A patent/EA036080B1/ru unknown
-
2017
- 2017-07-20 PH PH12017501318A patent/PH12017501318B1/en unknown
- 2017-07-24 IL IL253633A patent/IL253633B/en active IP Right Grant
- 2017-07-27 SA SA517382002A patent/SA517382002B1/ar unknown
- 2017-07-27 CL CL2017001924A patent/CL2017001924A1/es unknown
- 2017-08-21 ZA ZA2017/05663A patent/ZA201705663B/en unknown
- 2017-08-22 CO CONC2017/0008476A patent/CO2017008476A2/es unknown
-
2020
- 2020-08-06 JP JP2020133642A patent/JP7028923B2/ja active Active
-
2022
- 2022-11-02 CL CL2022003027A patent/CL2022003027A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506277A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2018509889A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| JP2019532617A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2017535257A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| JP2019530427A5 (enExample) | ||
| JP2015520758A5 (enExample) | ||
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2014519317A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2018521691A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2016505546A5 (enExample) | ||
| TW201138825A (en) | TNF-α binding proteins | |
| TW201031421A (en) | IL-1 binding proteins | |
| JP2012530496A5 (enExample) |